510(k) · Cleared
Recalled · Class I · 2025Dexcom G7 Continuous Glucose Monitoring System
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Dexcom, Inc. · QBJ Integrated Continuous Glucose Monitoring System, Factory Calibrated
Cleared on Dec 7, 2022 as substantially equivalent to K201328 (Dexcom, Inc., 2021) after a 357-day review. Its family tree reaches back 5 generations to 2018. 1 of the 20 devices in its family, counting itself, has a Class I recall. 12 later devices descend from it. It has been recalled 4 times, including 4 Class I recalls.
- Decided
- Dec 7, 2022
- Review
- 357 days
- Class
- Class II
- Product code
- QBJ
- Recalls
- 4 (4 Class I)
- Predicates
- 1
Its longest line of descent runs back 5 generations to DEN170088 (2018). 7 ancestors in all. 12 later devices descend from it, 1 citing it directly. 1 of the 20 devices in this family, counting this one, has a Class I recall.
- Root · 5 generations backDEN170088 Dexcom G6 Continuous Glucose Monitoring SystemDexcom, Inc. · 2018
- 4 generations backK182041 Dexcom G6 Glucose Program Continuous Glucose Monitoring SystemDexcom, Inc. · 2018
- 3 generations backK191450 Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose…Dexcom, Inc. · 2019 · Recalled
- 2 generations backK200876 Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose…Dexcom, Inc. · 2020 · Recalled
- 1 generation backK201328 Dexcom G6 Continuous Glucose Monitoring (CGM) SystemDexcom, Inc. · 2021
- This deviceK213919 Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc. · 2022
- Descendant · cites it directly · 11 of its ownK231081 Dexcom G7 Continuous Glucose Monitoring (CGM) SystemDexcom, Inc. · 2023 · Recalled
- Descendant · 2 generations on · 5 of its ownK234133 Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc. · 2024
- Descendant · 3 generations on · 4 of its ownK240902 Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc. · 2024 · Recalled
- Descendant · 2 generations on · 4 of its ownK234070 Stelo Glucose Biosensor SystemDexcom, Inc. · 2024
- Descendant · 4 generations on · 3 of its ownK243214 Dexcom G7 15 Day Continuous Glucose Monitoring SystemDexcom, Inc. · 2025 · Recalled
Showing 5 of 12 descendants. See all descendants
Descendants cleared per year
Most influential descendants
Showing 5 of 12 · See all- K231081Dexcom G7 Continuous Glucose Monitoring (CGM) SystemDexcom, Inc. · 2023 · cites it directly11descendants
- K234133Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc. · 2024 · 2 generations on5descendants
- K240902Dexcom G7 Continuous Glucose Monitoring SystemDexcom, Inc. · 2024 · 3 generations on4descendants
- K234070Stelo Glucose Biosensor SystemDexcom, Inc. · 2024 · 2 generations on4descendants
- K243214Dexcom G7 15 Day Continuous Glucose Monitoring SystemDexcom, Inc. · 2025 · 4 generations on3descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −5 | DEN170088 | Dexcom G6 Continuous Glucose Monitoring System | Dexcom, Inc. | 2018 | — |
| −4 | K182041 | Dexcom G6 Glucose Program Continuous Glucose Monitoring System | Dexcom, Inc. | 2018 | — |
| −3 | K191450 | Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose Program… | Dexcom, Inc. | 2019 | 2 |
| −2 | K200876 | Dexcom G6 Continuous Glucose Monitoring System, Dexcom G6 Glucose Program… | Dexcom, Inc. | 2020 | 1 |
| −1 | K201328 | Dexcom G6 Continuous Glucose Monitoring (CGM) System | Dexcom, Inc. | 2021 | — |
| 0 (this device) | K213919 | Dexcom G7 Continuous Glucose Monitoring System | Dexcom, Inc. | 2022 | — |
| +1 | K231081 | Dexcom G7 Continuous Glucose Monitoring (CGM) System | Dexcom, Inc. | 2023 | 1 |
| +2 | K234133 | Dexcom G7 Continuous Glucose Monitoring System | Dexcom, Inc. | 2024 | — |
| +3 | K240902 | Dexcom G7 Continuous Glucose Monitoring System | Dexcom, Inc. | 2024 | 3 |
| +2 | K234070 | Stelo Glucose Biosensor System | Dexcom, Inc. | 2024 | — |
| +4 | K243214 | Dexcom G7 15 Day Continuous Glucose Monitoring System | Dexcom, Inc. | 2025 | 2 |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2018 | 1 | 0 |
| 2019 | 1 | 0 |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2023 | 1 | 0 |
| 2024 | 3 | 0 |
| 2025 | 3 | 0 |
| 2026 | 5 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
1 device in this family has a Class I recall. A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new QBJ device
- #1 K253737 Dexcom G7 Continuous Glucose Monitoring (CGM)…score 16.5 · 10 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K201328 | Dexcom G6 Continuous Glucose Monitoring (CGM) SystemSummary page 5…e QBJ Review Panel Clinical Chemistry 5.3 PREDICATE DEVICE: Dexcom G6 Continuous Glucose Monitoring (CGM) System (K201328) 5.4 DEVICE DESCRIPTION: The Dexcom G7 Continuous Glucose Monitoring System (G7 System) is an interoperable connected de… | 2021 |
What descends from it? (12)
See all 121 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K231081 | Dexcom G7 Continuous Glucose Monitoring (CGM) System | 2023 | 11 |
Has anything in its family been recalled? (1 Class I)
Recalls of this device
| Date | Class | Recall | Root cause | Reason |
|---|---|---|---|---|
| Jul 24, 2025 | Class I | Z-2448-2025 | Software design | The affected devices are the Dexcom G7 Continuous Glucose Monitoring System (CGM System) using iOS, watchOS and Android App software (versions 2.8.0 or earlier) and Dexcom ONE+ CGM System using iOS and Android App software (versions 1.4.0… |
| Jul 24, 2025 | Class I | Z-2447-2025 | Software design | The affected devices are the Dexcom G7 Continuous Glucose Monitoring System (CGM System) using iOS, watchOS and Android App software (versions 2.8.0 or earlier) and Dexcom ONE+ CGM System using iOS and Android App software (versions 1.4.0… |
| Jul 24, 2025 | Class I | Z-2446-2025 | Software design | The affected devices are the Dexcom G7 Continuous Glucose Monitoring System (CGM System) using iOS, watchOS and Android App software (versions 2.8.0 or earlier) and Dexcom ONE+ CGM System using iOS and Android App software (versions 1.4.0… |
| May 12, 2025 | Class I | Z-1944-2025 | Nonconforming Material/Component | Defective foam or an assembly error may cause the receiver speaker to lose contact with the printed circuit board, leading to missed audible alerts for low or high blood glucose values. A missed audible alert for low or high blood glucose… |
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 4 years and passes through 1 company; a new generation was cleared every 8 months on median.
- 2 of the 7 ancestors have a recall of any class.
- Of its descendants, K231081 (Dexcom, Inc., 2023) has gone furthest, with 11 descendants of its own.
- 1 other device also cites its predicate K201328.
How does its category compare?
All QBJ devicesQBJ Integrated Continuous Glucose Monitoring System, Factory Calibrated: FDA decisions, review times, recalls and adverse event reports over 20 years. 2022, this device’s year, is highlighted.
FDA decisions per year · QBJ
2in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · QBJ
59in 2024
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · QBJ
4so far in 2026, the most since 2007
Class I (1 since 2007) Class II/III not classified
Adverse event reports per year · QBJ
374,651in 2025
MAUDE reports naming product code QBJ, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 3 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 0 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 0 |
| 2018 | 1 | — | 0 | 37,106 |
| 2019 | 2 | — | 0 | 80,774 |
| 2020 | 1 | — | 0 | 200,738 |
| 2021 | 1 | — | 0 | 254,833 |
| 2022 | 2 | — | 0 | 232,288 |
| 2023 | 4 | 89 | 0 | 273,565 |
| 2024 | 3 | 59 | 0 | 347,124 |
| 2025 | 2 | — | 2 (1) | 374,651 |
| 2026 | 2 | — | 4 | — |
What is it indicated for?
The Dexcom G7 Continuous Glucose Monitoring (CGM) System is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons 2 years and older. The Dexcom G7 CGM System is intended to replace fingerstick BG testing for diabetes treatment decisions. Interpretation of the Dexcom G7 CGM System results should be based on the glucose trends and several sequential sensor readings over time. The Dexcom G7 CGM System also…
Read the full statement (134 words)
The Dexcom G7 Continuous Glucose Monitoring (CGM) System is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons 2 years and older.
The Dexcom G7 CGM System is intended to replace fingerstick BG testing for diabetes treatment decisions. Interpretation of the Dexcom G7 CGM System results should be based on the glucose trends and several sequential sensor readings over time. The Dexcom G7 CGM System also aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments.
The Dexcom G7 CGM System is also intended to autonomously communicate with digitally connected devices, including automated insulin dosing (AID) systems. The Dexcom G7 CGM System can be used alone or in conjunction with these digitally connected medical devices for the purposes of managing diabetes.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K213919 · printed Nov 6, 2026
Cite this page
510(k) Report. “K213919: Dexcom G7 Continuous Glucose Monitoring System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K213919
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026